Loading...
•
Dec 31, 2024
Prestige Consumer Q3 2025 Earnings Report
Prestige Consumer Healthcare reported record quarterly sales and earnings per share, driven by strong international business performance and improved Clear Eyes revenues.
Key Takeaways
Prestige Consumer Healthcare Inc. reported a 2.7% increase in revenue to $290.3 million and diluted EPS of $1.22, up approximately 15% year-over-year. The company raised its full-year fiscal 2025 earnings outlook, driven by strong free cash flow and debt reduction.
Revenue increased by 2.7% to $290.3 million in Q3 2025 compared to the prior year.
Diluted EPS increased approximately 15% to $1.22 in Q3 2025.
Leverage reduced to 2.5x in Q3 2025 due to strong profitability and cash flow.
Full-year fiscal 2025 earnings outlook raised.
Prestige Consumer
Prestige Consumer
Prestige Consumer Revenue by Segment
Revenue by Segment
North American OTC Healthcare Revenue
CapyFin.comInternational OTC Healthcare Revenue
CapyFin.com Forward Guidance
The company raised its earnings outlook for fiscal year 2025, anticipating approximately 1% organic revenue growth and adjusted diluted EPS of approximately $4.50, supported by strong free cash flows.
Positive Outlook
- Achieve fiscal 2025 outlook.
- Approximately 1% organic revenue growth.
- Lower interest expense.
- Reduced shares outstanding.
- Strong financial performance.
Challenges Ahead
- No specific negatives were mentioned in the provided text.
Revenue & Expenses
Visualization of income flow from segment revenue to net income